Dataset Information

A novel Werner Syndrome mutation: pharmacological treatment by read-through of nonsense mutations and epigenetic therapies.

ABSTRACT: Werner Syndrome (WS) is a rare inherited disease characterized by premature aging and increased propensity for cancer. Mutations in the WRN gene can be of several types, including nonsense mutations, leading to a truncated protein form. WRN is a RecQ family member with both helicase and exonuclease activities, and it participates in several cell metabolic pathways, including DNA replication, DNA repair, and telomere maintenance. Here, we reported a novel homozygous WS mutation (c.3767 C > G) in 2 Argentinian brothers, which resulted in a stop codon and a truncated protein (p.S1256X). We also observed increased WRN promoter methylation in the cells of patients and decreased messenger WRN RNA (WRN mRNA) expression. Finally, we showed that the read-through of nonsense mutation pharmacologic treatment with both aminoglycosides (AGs) and ataluren (PTC-124) in these cells restores full-length protein expression and WRN functionality.

SUBMITTER: Agrelo R

PROVIDER: S-EPMC4622951 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

A novel Werner Syndrome mutation: pharmacological treatment by read-through of nonsense mutations and epigenetic therapies.

Agrelo Ruben R Sutz Miguel Arocena MA Setien Fernando F Aldunate Fabian F Esteller Manel M Da Costa Valeria V Achenbach Ricardo R

Epigenetics 20150101 4

Werner Syndrome (WS) is a rare inherited disease characterized by premature aging and increased propensity for cancer. Mutations in the WRN gene can be of several types, including nonsense mutations, leading to a truncated protein form. WRN is a RecQ family member with both helicase and exonuclease activities, and it participates in several cell metabolic pathways, including DNA replication, DNA repair, and telomere maintenance. Here, we reported a novel homozygous WS mutation (c.3767 C > G) in ...[more]

PMID: 25830902

Dataset Information

A novel Werner Syndrome mutation: pharmacological treatment by read-through of nonsense mutations and epigenetic therapies.

Publications

A novel Werner Syndrome mutation: pharmacological treatment by read-through of nonsense mutations and epigenetic therapies.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Similar Datasets

Translational read-through of a nonsense mutation causing Bartter syndrome.
| S-EPMC3677996 | biostudies-literature

Pharmacological read-through of nonsense ARSB mutations as a potential therapeutic approach for mucopolysaccharidosis VI.
| S-EPMC3590409 | biostudies-literature

Translational Read-Through Therapy of RPGR Nonsense Mutations.
| S-EPMC7697989 | biostudies-literature

Accelerated epigenetic aging in Werner syndrome.
| S-EPMC5425119 | biostudies-literature

Transcriptional Read-Through Induction Treatment Trial in Intestinal Failure Induced by an EpCAM Nonsense Mutation.
| S-EPMC3444051 | biostudies-literature

Translational read-through of a nonsense mutation in ATP7A impacts treatment outcome in Menkes disease.
| S-EPMC2917729 | biostudies-literature

Read-through strategies for suppression of nonsense mutations in Duchenne/ Becker muscular dystrophy: aminoglycosides and ataluren (PTC124).
| S-EPMC3674569 | biostudies-literature

Aminoglycoside drugs induce efficient read-through of <i>CDKL5</i> nonsense mutations, slightly restoring its kinase activity.
| S-EPMC6779400 | biostudies-literature

Pharmacological read-through of R294X Mecp2 in a novel mouse model of Rett syndrome.
| S-EPMC7471501 | biostudies-literature

Targeted long-read sequencing identifies missing pathogenic variants in unsolved Werner syndrome cases.
| S-EPMC9613861 | biostudies-literature